Cargando…

Patterns of Care and Outcome Analysis of Nasopharyngeal Carcinoma: An Indonesian Single Institution Study

BACKGROUND: Nasopharyngeal cancer is endemic to Southeast Asia. However, there is limited clinical evidence of nasopharyngeal cancer in Indonesia, which has the largest population in Southeast Asia. METHODS: Patterns of care and treatment outcomes in 428 patients with newly-diagnosed and pathologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Faisal, Hamida Hayati, Kubo, Nobuteru, Nuryadi, Endang, Prihartono, Joedo, Atmakusuma, Tubagus Djumhana, Rachmadi, Lisnawati, Oike, Takahiro, Nakano, Takashi, Gondhowiardjo, Soehartati A, Adham, Marlinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541880/
https://www.ncbi.nlm.nih.gov/pubmed/32458659
http://dx.doi.org/10.31557/APJCP.2020.21.5.1481
Descripción
Sumario:BACKGROUND: Nasopharyngeal cancer is endemic to Southeast Asia. However, there is limited clinical evidence of nasopharyngeal cancer in Indonesia, which has the largest population in Southeast Asia. METHODS: Patterns of care and treatment outcomes in 428 patients with newly-diagnosed and pathologically-confirmed nasopharyngeal cancer were retrospectively analyzed. RESULTS: Concurrent chemo-radiotherapy (CCRT) was the first-line treatment for stages I–IVB diseases. The 2-year overall survival (OS) of all patients were 100.0%, 100.0%, 93.8%, 86.2%, 82.9%, and 62.4% for stages I, II, III, IVA, IVB, and IVC, respectively. The 2-year OS of CCRT-treated patients were 100.0%, 100.0%, 92.6%, 82.4%, and 78.3% for stages I, II, III, IVA, and IVB, respectively. CONCLUSION: The patterns of care and treatment outcomes were potentially consistent with world standards, needing future validation. This is the largest study of newly diagnosed nasopharyngeal cancer in Indonesia, a huge disease burden, providing an important basis for the clinical management of this disease.